Evidence map›Paper›PMID 25469985›Full record

SynthesisPloS one2014

Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis.

Ya Li, Bingyin Shi, Sheli Li

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Mechanisms by which obesity regulates inflammation and anti-tumor immunity in cancer.Biochemical and biophysical research communications · 2024
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Chemerin is resident to vascular tunicas and contributes to vascular tone.American journal of physiology. Heart and circulatory physiology · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ya LiDepartment of endocrinology, The First Hospital Affiliated to Xi'an Jiaotong University, Xi'an 710061, China; Department of endocrinology, Yan'an University Affiliated Hospital, Yan'an 716000, China.
Bingyin ShiDepartment of endocrinology, The First Hospital Affiliated to Xi'an Jiaotong University, Xi'an 710061, China.
Sheli LiDepartment of endocrinology, Yan'an University Affiliated Hospital, Yan'an 716000, China.
First Affiliated Hospital of Xi'an Jiaotong University · CNYanan University Affiliated Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveChemerin is a novel adipokine. Previous research has investigated the association between chemerin and clinical indices in patients with obesity or metabolic syndrome (MS), although the results obtained have been inconsistent. We conducted a meta-analysis to investigate the association between chemerin and clinical indicators of diabetes, MS and obesity with obesity or MS subjects. DESIGN AND

methodsStudies were identified by searching the PubMed, the Cochrane Library, EMBASE and CNKI, databases beginning with the original report in July 2007 until the end of May 2013. For each variable, summary correlation coefficients were estimated using random-effects or fixed-effect meta-analysis with 95% confidence interval (CI) performed by STATA software.

resultsA total of eight studies with 20 clinical variables (total n = 1787) met the inclusion criteria. The meta-analyse of diabetes markers showed that FSI (rs = 0.26; 95% CI = 0.21-0.31; P = 0.000), 2HPG (rs = 0.06; 95% CI = 0.01-0.12; P = 0.030) and HOMA-IR (rs = 0.178; 95% CI = 0.019-0.337; P = 0.028) were positively correlated with chemerin, however, FPG (rs = 0.03, 95% CI = -0.02 to 0.08, P = 0.240) and HbA1c (rs = -0.05; 95% CI = -0.24-0.15; P = 0.641) were not significantly correlated with chemerin. The meta-analyses of MS and obesity markers indicated that TG, TC, CRP BMI, TBF%, WC, WHR and Leptin were positively correlated with chemerin, nevertheless, SBP, DBP, LDL-C, HDL-C, ALT and r-GT were not significantly correlated, adiponectin was negatively correlated. Sensitivity analysis was performed and the summary results did not change significantly.

conclusionsThe results suggest that chemerin in patients with obesity or MS may be associated with obesity, imbalances in lipid and diabetes metabolism and insulin resistance. Chemerin played an important role in the pathophysiology of obesity and MS.

Indexed as

Body Mass IndexChemokinesCholesterolC-Reactive ProteinDiabetes MellitusHumansInsulin ResistanceIntercellular Signaling Peptides and ProteinsMetabolic SyndromeObesityTriglyceridesChemokinesCholesterolC-Reactive ProteinIntercellular Signaling Peptides and ProteinsRARRES2 protein, humanTriglycerides

Identifiers

PMID25469985
PMCPMC4254750
OpenAlexW2071816014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.